3.63

2.16% -0.08

Pre-market: 3.63

Abcellera Biologics Inc (ABCL)

Overview News Price History Option Chain Financials Why ABCL Down? Discussions Forecast

Abcellera Biologics Inc stock is traded at $3.63, with a volume of 3.15M. It is down -2.16% in the last 24 hours and up +11.01% over the past month. AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Previous Close:

$3.71

Open:

$3.7

24h Volume:

3.15M

Relative Volume:

0.75

Market Cap:

$1.10B

Revenue:

$38.03M

Net Income/Loss:

$-146.40M

P/E Ratio:

-6.9808

EPS:

-0.52

Net Cash Flow:

$-121.38M

1W Performance:

+13.79%

1M Performance:

+11.01%

6M Performance:

-12.74%

1Y Performance:

+55.13%

1-Day Range:

$3.60

$3.7583

1-Week Range:

$3.1505

$3.835

52-Week Range:

$1.8906

$6.515

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name

Abcellera Biologics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

(604) 559-9005

Address

150 W 4TH AVENUE, VANCOUVER

Employee

562

Twitter

Next Earnings Date

2024-11-18

Latest SEC Filings

ABCL's Discussions on Twitter

Compare ABCL vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABCL Abcellera Biologics Inc	3.63	1.12B	38.03M	-146.40M	-121.38M	-0.52
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-07-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-07-25	Resumed	Leerink Partners	Outperform
Aug-20-24	Downgrade	The Benchmark Company	Buy → Hold
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy
Nov-16-22	Initiated	Truist	Buy
Dec-21-21	Initiated	The Benchmark Company	Buy
Nov-19-21	Initiated	Piper Sandler	Overweight
Jan-05-21	Initiated	BMO Capital Markets	Outperform
Jan-05-21	Initiated	Berenberg	Buy
Jan-05-21	Initiated	Credit Suisse	Outperform
Jan-05-21	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	Stifel	Buy

View All

Abcellera Biologics Inc Stock (ABCL) Latest News

Mar 04, 2026

AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says - MarketBeat

Mar 04, 2026

AbCellera at TD Cowen Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada

Mar 04, 2026

Mar 03, 2026

DNB Asset Management AS Buys Shares of 656,208 AbCellera Biologics Inc. $ABCL - MarketBeat

Mar 03, 2026

Mar 02, 2026

Holdings Thermopylae Increases Stake in AbCellera Biologics Inc - GuruFocus

Mar 02, 2026

Thermopylae adds AbCellera (ABCL) shares in open-market buy - Stock Titan

Mar 02, 2026

Feb 28, 2026

AbCellera (ABCL) Is Up 18.8% After Pivoting To Clinical Stage And Filing Share Offering - simplywall.st

Feb 28, 2026

Feb 27, 2026

Thermopylae Holdings adds AbCellera (ABCL) shares in $3.27 open-market buy - Stock Titan

Feb 27, 2026